Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
EBIATLong-Term Debt RepaymentsShares Issued
Ratios

Solid Biosciences (SLDB) Shares Issued (2018 - 2024)

Solid Biosciences (SLDB) has disclosed Shares Issued for 5 consecutive years, with $19000.0 as the latest value for Q4 2024.

  • Quarterly Shares Issued changed N/A to $19000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Dec 2024, down 88.45% year-over-year, with the annual reading at $6000.0 for FY2025, 98.69% down from the prior year.
  • Shares Issued hit $19000.0 in Q4 2024 for Solid Biosciences, down from $3.1 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $134.9 million in Q1 2021 to a low of $19000.0 in Q4 2024.
  • Historically, Shares Issued has averaged $27.3 million across 4 years, with a median of $2.8 million in 2023.
  • Biggest five-year swings in Shares Issued: plummeted 99.98% in 2022 and later surged 112.68% in 2024.
  • Year by year, Shares Issued stood at $134.9 million in 2021, then crashed by 46.23% to $72.5 million in 2022, then plummeted by 96.5% to $2.5 million in 2023, then crashed by 99.25% to $19000.0 in 2024.
  • Business Quant data shows Shares Issued for SLDB at $19000.0 in Q4 2024, $3.1 million in Q3 2024, and $5.4 million in Q2 2024.